Kolmar Korea Eyes Pharma Expansion Via CJ HealthCare Acquisition
The acquisition of mid-size South Korean pharma firm CJ HealthCare is set to boost Kolmar Korea's pharma business, enabling the cosmetics and pharma company to transform into a larger and more integrated healthcare firm.
You may also be interested in...
South Korean pharma HK inno.N’s $500m IPO has drawn strong interest with subscriptions from institutional investors marking a record high. The IPO should help it speed up development of cell and gene therapies and beef up its vaccines business.
Scrip takes a look at Korean out-licensing deal trends and rankings in 2018, finding biotech-related transactions were dominant.
As the year end approaches, Scrip wraps up what major events made headlines in the South Korean pharma/biotech sector in 2018.